In conclusion, the thorough identification of the mechanism of action of GDF15 is desirable to open the doors to translational perspective: elucidating if and how elevated plasma levels of this peptide can have direct repercussions in gastric physiology and appetite regulation promises possible clinical applications in the treatment of eating disorders and obesity, as well as nausea and vomiting. This evidence concerns the gene GDF15 and obesity disorder.